Discover our Portfolio



Altimmune is a clinical biotechnology company located in Maryland (USA); the company develops immunotherapies for several diseases, including acute respiratory infections and chronic viral infections, capitalizing on two innovative vaccine distribution platforms: RepirVec ™ and Densigen ™.



Altimmune’s positive progress was announced at the end Q1 2018:


  • On the vaccine program NasoVax™ (licensed injectable seasonal influenza vaccine): proof of concept positive from phase 2a clinical trial


  • Positive preclinical survival and immunogenicity data for the Phase 2 SparVax-L program (prevention of anthrax infection)


The positive results of the NasoVAX study enable to look forward to a new approach to fight influenza; NasoVAX could become effective and easy to administer flu vaccine which may offer broader and longer lasting protection than current vaccines.


Contact Truffle Capital

7 + 12 =

[sg_popup id=2]
5 Rue de la Baume, 75008 Paris, France Tel: +33 1 82 28 46 00



Truffle Capital

Truffle Capital

5 Rue de la Baume 75008 Paris France
Tel: +33 1 82 28 46 00

© 2018 Truffle Capital

Truffle Capital 2018

Social Networks